July 6, 2017 10:31 AM EDT

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

John Carroll

Editor & Founder

Oxford BioMedica has scored a major supply contract with Novartis for the lentiviral vectors the pharma giant uses in its CAR-T drugs, including the industry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis turns to Ox­ford Bio­Med­ica for a ma­jor CAR-T sup­ply deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test